Apitegromab

Phase 3

Scholar Rock Holding Corporation (SRRK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

SRRKPhase 3$5.7B

Apitegromab Phase 3 Est. Readout

Apitegromab• Spinal Muscular Atrophy238

Nov 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Spinal Muscular Atrophy

View Full Landscape

Drug Information

Target Indication

Spinal Muscular Atrophy

Clinical Trial

NCT07047144

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Isembyld

Treatment of muscular atrophy in patients aged 2 years and older, with 5q spinal muscular atrophy (SMA), who are non-ambulatory and currently receiving a survival motor neuron 2 (SMN2) targeted treatment

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SRRK

Scholar Rock Holding Corporation

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

SRK-015Phase 2

Spinal Muscular Atrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts